EICHORPublic-registry site landscape for NCT05039359, “Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation”, a Paroxysmal Atrial Fibrillation study sponsored by InCarda Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05039359 (registry record) |
| Study title | Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm |
| Sponsor | InCarda Therapeutics, Inc. |
| Condition(s) | Paroxysmal Atrial Fibrillation |
| Phase | PHASE3 |
| Listed sites | 40 |
| Intervention(s) | FlecIH-103 |
| Site countries | United States, Czechia, Hungary, Netherlands, Poland, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT05039359.
Eichor generates a preliminary site-risk snapshot for NCT05039359 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
